Navigation Links
VETORYL(R) (Trilostane) Receives FDA Approval
Date:12/15/2008

OVERLAND PARK, Kan., Dec. 15 /PRNewswire/ -- Dechra Veterinary Products LLC today announces that the company has received FDA approval to market VETORYL(R) Capsules.

VETORYL Capsules contain the drug trilostane, which has been demonstrated to be effective in the treatment of Cushing's syndrome in dogs. VETORYL will be indicated for use in pituitary-dependent hyperadrenocorticism, which comprises the majority of cases of Cushing's syndrome in dogs. Additionally, VETORYL has received designation status as a Minor Use Drug for treatment of hyperadrenocorticism caused by adrenal tumors -- the first drug to receive an approval for this indication and the first drug to receive a Minor Use designation in dogs.

Mike Eldred, President of U.S. Operations, says, "We are very excited to have approval to market this novel product in the U.S. Following its launch in January, veterinarians will be able to source the product through our network of distribution partners."

Dechra Veterinary Products LLC, located in Overland Park, Kansas, is the U.S. subsidiary of Dechra Pharmaceuticals PLC, a UK listed company focused on international animal healthcare markets. Dechra currently markets a range of specialized veterinary products in the U.S. For more information, please visit http://www.dechra-us.com or call 866-933-2472.


'/>"/>
SOURCE Dechra Veterinary Products LLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
2. DaVita Receives Civil Complaint
3. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
4. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
5. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
6. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
7. UT Southwesterns obesity research receives $22 million NIH Roadmap grant
8. Temple Emergency Medicine receives $1.8M to find best MRSA treatment
9. Prime Therapeutics Receives TIPPS Certification
10. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
11. UCLA receives $22.5 million to explore the fundamental biology of mental disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... 25, 2017 , ... A recent report from the Wisconsin ... the 2015-16 school year across Wisconsin’s public schools, charter schools, and private schools ... in student test score performance, the report’s limited analyses fail to provide answers ...
(Date:4/25/2017)... ... April 25, 2017 , ... As pharmaceutical companies are held ... with process innovation in drug formulation and manufacturing. CoreRx offers its clients ... equipment in support of their development and manufacturing goals. , The company ...
(Date:4/25/2017)... ... ... Chaudhary, MD is committed to providing the highest quality of spine care to all his ... with all my patients to alleviate possible future issues. I am pleased to have you ... and my trained staff will assist you in any way possible.” , Dr. Saad Chaudhary ...
(Date:4/25/2017)... ... 25, 2017 , ... Vetoquinol USA® , a world-class ... part of the EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in ... immunologic level. , The scientifically-developed Flexadin UCII supports the body’s normal repair of ...
(Date:4/24/2017)... Nashville, TN (PRWEB) , ... April 24, 2017 , ... ... electrifying fans and transforming the quarterback position. The former overall number one pick in ... his professional football career. He holds the record for the most career rushing yards ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... Research and Markets has announced ... Market Prospects: Addressing Production Complexities Through Risk Management and ... ... Pipeline and Market Prospects: Overcoming Production Complexities Through Risk ... of the current trends in the global biosimilars market, ...
(Date:4/20/2017)... , April 20, 2017 Research and ... Technologies - Innovation Driven by Rapidly Expanding Injectables Market and Increasing ... their offering. ... for drug delivery technologies will rise from USD 20 Billion in ... Global Drug Delivery Technologies - Innovation Driven by Rapidly Expanding ...
(Date:4/20/2017)... --  ZappRx, Inc ., a digital health company focused on ... it closed $25 million in Series B funding led by ... Seattle that is part of a ... B round included participation from SR One , who ... (formerly Google Ventures). As part of the financing, ...
Breaking Medicine Technology: